Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations
ContributorsTaverna, C.; Bargetzi, M.; Betticher, D.; Gmur, J.; Gregor, M.; Heim, D.; Hess, U.; Ketterer, N.; Lerch, E.; Matthes, Thomas; Mey, U.; Pabst, T.; Renner, Christoph
Published inSchweizerische medizinische Wochenschrift, vol. 140, w13054
Publication date2010
Abstract
Keywords
- Aged
- Antineoplastic Agents/adverse effects/*therapeutic use
- Biopsy, Needle
- Bone Marrow/drug effects/pathology
- Bone Marrow Transplantation
- Boronic Acids/adverse effects/therapeutic use
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- *Evidence-Based Medicine
- Humans
- Middle Aged
- Multiple Myeloma/diagnosis/*drug therapy/pathology
- Neoplasm Recurrence, Local/drug therapy/pathology
- Plasma Cells/drug effects/pathology
- Pyrazines/adverse effects/therapeutic use
- Retreatment
- Switzerland
- Thalidomide/adverse effects/analogs & derivatives/therapeutic use
Affiliation
Citation (ISO format)
TAVERNA, C. et al. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. In: Schweizerische medizinische Wochenschrift, 2010, vol. 140, p. w13054. doi: 10.4414/smw.2010.13054
Identifiers
- PID : unige:20569
- DOI : 10.4414/smw.2010.13054
- PMID : 20458652
ISSN of the journal0036-7672